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Abstract
Background: Breast Cancer (BC) is a known global crisis. The
World Health Organization reports a global 2.09 million inci-
dences and 627,000 deaths in 2018 relating to BC. The traditional
BC screening method in developed countries is mammography,
whilst developing countries employ breast self-examination and
clinical breast examination. The prominent gold standard for BC
detection is triple assessment: i) clinical examination, ii) mam-
mography and/or ultrasonography; and iii) Fine Needle Aspirate
Cytology. However, the introduction of cheaper, efficient and non-
invasive methods of BC screening and detection would be benefi-
cial.  
Design and methods: We propose the use of eight machine
learning algorithms: i) Logistic Regression; ii) Support Vector
Machine; iii) K-Nearest Neighbors; iv) Decision Tree; v) Random
Forest; vi) Adaptive Boosting; vii) Gradient Boosting; viii)
eXtreme Gradient Boosting, and blood test results using BC
Coimbra Dataset (BCCD) from University of California Irvine
online database to create models for BC prediction. To ensure the
models’ robustness, we will employ: i) Stratified k-fold Cross-
Validation; ii) Correlation-based Feature Selection (CFS); and iii)
parameter tuning. The models will be validated on validation and
test sets of BCCD for full features and reduced features. Feature
reduction has an impact on algorithm performance. Seven metrics
will be used for model evaluation, including accuracy.
Expected impact of the study for public health: The CFS
together with highest performing model(s) can serve to identify
important specific blood tests that point towards BC, which may
serve as an important BC biomarker. Highest performing model(s)
may eventually be used to create an Artificial Intelligence tool to
assist clinicians in BC screening and detection.
Introduction
A brief overview of breast cancer
Breast Cancer (BC) is a deadly disease known to be a global
crisis. According to the World Health Organization, in the year
2018, BC was reported to have the highest number of cancer inci-
dences globally, equating to approximately 2.09 million cases.1 In
addition, BC was also the fifth most common cause of cancer
death, with 627,000 BC death cases.1 Breast cancer is most com-
monly diagnosed in women; however, it can also affect men.    
Traditional breast cancer screening methods
The screening of BC is important because it allows for early
detection and reduction of BC mortality rates. Developed and
developing countries employ different methods for BC screening.
This is due to the varied nature of the type of resources available
in a country. Developed countries utilize mammography for BC
screening.2 However, mammography is both expensive and com-
plicated, which results in a financial burden for the patient and the
need for specialist clinicians to perform mammography.
Moreover, studies have shown varied outcomes on whether or not
mammography truly results in decreased BC mortality rates.3
Developing countries rely on: i) Breast Self-Examination
(BSE); and ii) Clinical Breast Examination (CBE) for BC screen-
ing.3 The BSE involves individuals regularly checking their
breasts for signs of a lump or anything out of the ordinary. If there
are any peculiar differences in the breast, the person would need
to approach a clinician. The clinician would then perform a breast
examination on the effected person. These two processes are rela-
tively easier and cheaper, in comparison to mammography.
However, there is no empirical evidence that BSE or CBE results
in reduced BC mortality rates.3
Traditional breast cancer detection methods
The triple assessment test, known as ‘the gold standard’, is the
most prominent method employed worldwide for BC detection.
This test consists of a combination of three medical tests: i) clini-
cal examination; ii) radiological imaging (mammography and/ or
ultrasonography); and iii) pathology (Fine Needle Aspirate
Cytology (FNAC) or core needle biopsy).4 The combined, final
result of these tests is known to provide an estimated sensitivity of
99%. Clinicians interpret the results of this triple assessment as
follows: if the result of at least one of the three tests indicates pos-
itive malignancy, the patient is flagged as having BC, whereas if
the results for all the three tests indicate benign, the overall result
for a patient is benign.4
The conventional methods for estimation of the presence of
Significance for public health
This study could potentially identify important Breast Cancer (BC) biomark-
ers based on patients’ routine anthropometric blood data. This will be
attempted using correlation-based feature selection algorithm, together with
highest performing machine learning model(s) from this study, and publicly
available BC Coimbra Dataset from University of California Irvine database.
The biomarkers may provide direction for clinicians to explore in future BC
clinical trials. Trials will serve to validate biomarkers from this study and
could be introduced in clinical settings globally as an easy, cost-effective first
step for BC screening and detection. An Artificial Intelligence tool can even-
tually be created using highest performing model(s). Clinicians can input
patient-specific biomarkers into the tool. The tool would output the likeli-
hood of patients having BC, with a certain level of accuracy. This envisioned
process could serve to eventually revolutionize the early prediction of BC in
patients and consequently, a reduction in BC mortality rate.
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diseases such as BC in medicine has been based on regression.5,6
The regression model will assume the risk factors of BC to be lin-
early related.7 In real-life situations, these factors are not often lin-
early related and regression methods may fail to capture all the risk
factors of BC.7 An alternative approach, which does not assume
linearity, is the Machine Learning approach.          
What is machine learning?
Machine Learning (ML) involves programming computers to
learn patterns from data in a specific domain by creating mathe-
matical models.8 In its simplest form, ML is a two-step process.
First, a model is built using sample data as input, termed the ‘train-
ing set’, and the model is also given the correct outputs. Various
ML algorithms, such as Logistic Regression (LR), can be used to
create models. After training the model, the model is tested using
unseen data, termed the ‘test set’. During the testing stage, the
model is expected to predict the output of the test set, which it does
with a certain level of performance. If a model performs well for
both training and testing, the model is considered to be good and
vice versa.
Machine learning and breast cancer prediction
A considerable amount of literature has been published on BC
prediction using ML models. The BC datasets from the University
of California Irvine (UCI) is a benchmark online database that has
mostly been used as the focus in much of the literature.9 Nithya
and Santhi achieved 97.8% accuracy using an ensemble algorithm
called multiboost.10 Wang and Yoon later used two different BC
datasets and created ML models using four different ML algo-
rithms.11 The highest performing models from this study by 10-
fold cross-validation were the hybrid Support Vector Machine
(SVM) model, with 97.47% accuracy, for one of the datasets and,
for the other dataset, the hybrid Artificial Neural Network model
achieved 99.63% accuracy.11 Chaurasia and Pal created three dif-
ferent models using a BC dataset and obtained 96.19% perfor-
mance using the Sequential Minimal Optimization algorithm.12 All
these studies have focused on BC datasets published during the
1990s, which are now outdated. Furthermore, these datasets are
based on invasive BC tests such as FNAC. 
In 2018, a new BC dataset, BC Coimbra Dataset (BCCD), was
uploaded to the UCI database using primary data.13 Compared to
older BC datasets, BCCD is based on patients’ routine anthropo-
metric blood analysis data. This data is cheap, easily accessible and
a non-invasive way of testing for BC. The above study achieved
the highest performing model using SVM and a subset of features
from the BCCD: i) Glucose; ii) Resistin; iii) Age; and iv) BMI with
sensitivity between 82% and 88%.13 Later, Li and Chen created
different models using the BCCD and an older BC dataset.14 The
Random Forest (RF) algorithm was found to be the primary model
for both datasets, with 74% accuracy on the BCCD and 96% accu-
racy on the older dataset.        
Our proposed first approach for breast cancer screen-
ing and detection
In this study, we will use the BCCD and some ML algorithms
such as: i) LR; ii) SVM; iii) K-Nearest Neighbors (K-NN); iv)
Decision Tree (DT); v) RF; vi) Adaptive Boosting (AdaBoost); vii)
Gradient Boosting Machine (GBM); and viii) eXtreme Gradient
Boosting (XGBoost) to create models with and without feature
selection (so in total, 16 models will be created). The LR algorithm
was chosen because it is generally the first algorithm attempted for
ML tasks. The SVM, K-NN and ensemble algorithms (RF,
AdaBoost, GBM and XGBoost) were chosen based on the Scikit-
Learn (the Python package that will be used in this study) guideline
from ‘start’ to ‘classification’ for ‘<100K samples’ of non-text data
from: https://scikit-learn.org/stable/tutorial/machine_learning_
map/index.html. The DT algorithm was chosen because it is the
base algorithm for RF, AdaBoost, GBM and XGBoost and there-
fore, also forms a basis for comparison. The creation of these 16
models also increases the likelihood of discovering a high-per-
forming model in this study amongst the base and ensemble algo-
rithms, with and without feature selection. We will also use param-
eter tuning and Stratified k-fold Cross-Validation (SCV) for all
models. The aim is to identify the best performing model(s) for the
purpose of BC classification. The best model(s) can later be used
to create an Artificial Intelligence (AI) tool to assist clinicians with
BC prediction as a first-step for screening and detection. This envi-
sioned process is illustrated in Figure 1. Utilizing this AI tool
would be beneficial because it would likely expedite the process of
identifying BC and improve clinicians’ predictions.   
Research questions
This research study aims to address the following research
questions:
Research Question 01: Which ML model(s) from this study
best enable(s) the prediction of BC using patients’ routine anthro-
pometric blood analysis data?
Research Question 02: Does the ML model(s) that best
enable(s) the prediction of BC from this study outperform the best
models from the literature?
Hypotheses 
The null hypothesis (H0) and the alternative hypothesis (HA)
for the respective research questions are outlined below.
H0(1): The performance of all the different ML models created
within this proposed study are the same for the prediction of BC. 
HA(1): The performance of at least one of the different ML
models created within this proposed study outperforms the remain-
ing models in this study, for the prediction of BC.
H0(2): All of the best performing ML model(s) created within
this proposed study do(es) not outperform the best models created
from the literature in the prediction of BC. 
HA(2): At least one of the best performing ML model(s) created
within this proposed study do(es) outperform the best models cre-
ated from the literature in the prediction of BC.
Research goal
The goal of this research is to contribute towards the develop-
ment of an AI tool, driven by ML model(s), for identifying BC in
patients, utilizing patients’ routine anthropometric blood analysis
data.
Research objectives
In order to achieve the research goal and address the research ques-
tions, the following objectives form the basis of this study:
i. To investigate which subset of features from the BCCD result
in the best performing models, based on the elimination of
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highly positively correlated features, implying redundant fea-
tures, using Correlation-based Feature Selection (CFS) algo-
rithm;
ii. To determine the correct values for different parameters of the
respective ML models, that result in the best performance per
model using parameter tuning;
iii. To identify the best performing ML model(s) in this study that
optimally enable(s) the prediction of BC; and 
iv. To examine whether the best performing ML model(s) in this
study also outperform(s) the existing ML models from the lit-
erature concerning BC prediction.
Materials and methods
The following subsections briefly discuss the materials and
methods that will be used in this study.
Data source
The BCCD available from the online UCI database will be
used in this study. This dataset contains anthropometric blood anal-
ysis data from female BC patients and volunteer healthy controls.13
The dataset has 116 rows and ten quantitative features. From the
116 rows, 55% (64 rows) belong to ‘BC tumour present’ and 45%
(52 rows) belong to ‘BC tumour absent’ group. The ten features
comprise of one dependant feature called ‘classification’, which is
used to indicate whether data belongs to ‘BC tumour present’ (clas-
sification equals ‘2’) or ‘BC tumour absent’ group (classification
equals ‘1’), while the remaining nine independent features are
blood analysis data. An overview of BCCD is found in:
https://archive.ics.uci.edu/ml/datasets/Breast+Cancer+Coimbra.  
Proposed hybrid framework of the modelling process
The aim of this modelling process is to classify people into
‘BC tumour present’ or ‘BC tumour absent’ groups. Since there are
two options for classification, this is known as ‘binary classifica-
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Figure 1. Global traditional versus proposed breast cancer screening and detection methods, indicating that the best performing
model(s) can eventually be used as basis to create an Artificial Intelligence (AI) tool as a first approach to identify breast cancer in
patients. 
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tion’. The performance of different ML models for predicting BC
will be tested on both the full features and selected features of the
BCCD.  Figure 2 depicts the framework of this modelling process.
Feature selection
With feature selection, only the most important features from a
dataset are used to build ML models. This is important because
having irrelevant features as input into a model results in poor per-
formance.15 We will use CFS in our models. The values for CFS
range from minus one to positive one. If two or more features are
found to be closer to minus one, the features are strongly negative-
ly correlated. Values closer to positive one mean that the features
are strongly positively related. For features having strong positive
correlation, we will remove all but keep only one of the features,
since including all is considered redundant information. We chose
CFS because it is easy to compute. The CFS can be done once-off
and utilized for all the models in our study. The CFS will enable us
to achieve objective (i) so that we can answer research question 01.    
Split breast cancer Coimbra dataset three ways:
Training set (60%), validation set (30%) and test set
(10%)
The BCCD will be split three ways: 60% training, 30% valida-
tion and 10% test sets. The 60% training portion will be used for
the training stage. The validation part will be used to provide
insights into tuning parameters. The test set will be used in the final
stage, to provide an unbiased evaluation of the models’ perfor-
mances. If a model performs well for both validation and test sets,
this will mean that the model is robust.    
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Figure 2. Proposed hybrid framework of the modelling process to predict breast cancer using the online breast cancer Coimbra Dataset
(BCCD) and various machine learning algorithms: Logistic Regression (LR), Support Vector Machine (SVM), K-Nearest Neighbors (K-
NN), Decision Tree (DT), Random Forest (RF), Adaptive Boosting (AdaBoost), Gradient Boosting Machine (GBM) and eXtreme
Gradient Boosting (XGBoost).
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Machine learning algorithms
Models will be created using the following eight ML algo-
rithms. 
Logistic regression 
The LR is a binary classification algorithm. A prediction (ŷ ) is
made by utilizing logistic function, given by Eq. 1:16
                                                                                                 
                                                                                                       
                                                          
1
The LR algorithm makes decisions based on the probability of
what is identified when the function is provided with a specific set
of features. Generally, the final output would be two or more class-
es. In our study, this function would output either of the two class-
es: i) BC tumour present (classification equals ‘2’); or ii) BC
tumour absent (classification equals ‘1’). We chose this algorithm
because it is generally the first algorithm attempted for ML prob-
lems and is known to produce good results for binary classifica-
tion.  
Support vector machine
The SVM algorithm takes data as input and outputs the most
optimal line, termed the decision boundary, in the middle that best
separates different groups of data it finds on a graph.17 This deci-
sion boundary would be drawn in the middle of peripheral data
points it finds, referred to as the ‘support vectors’ of the groups.17
In its simplest form, SVM would separate data into two groups in
a two-dimensional graph. In our study, the goal of SVM would be
to output the decision boundary to classify data into ‘BC tumour
present’ and ‘BC tumour absent’ groups. We chose the SVM algo-
rithm because it is known to perform well on medical data for clas-
sification into two groups, and it is a very popular algorithm.    
K-nearest neighbors
The K-NN algorithm is a simple technique used to classify
unlabelled data points based on the classification of neighbouring
labelled data points on a graph.17 The neighbouring data points
would be those closest in distance to the current data point. The
number of closest data points to reference is determined by the
value of a parameter called k. This is essentially a voting process.
The value of k is arbitrary, but choosing the optimal value for k is
important to ensure that a suitable number of neighbours is utilized
during the voting process so that errors cancel out each other and
the algorithm identifies correct patterns during this process.17 In its
simplest form, K-NN works on data in a two-dimensional graph. In
our case, this would be to classify ‘BC tumour present’ and ‘BC
tumour absent’.
Decision tree
The DT is known to be highly efficient and provides easy inter-
pretation due to its rule-based flowchart-like structure. This algo-
rithm starts with a question at the top, which is also termed a ‘root
node’. In a standard DT, answers for this underlying question have
two options. In our study, this underlying question would be simi-
lar to: ‘Is your BMI less than x?’ or ‘Is your BMI greater than or
equal to x?’. To answer this question, the algorithm would traverse
the tree branches depending on responses to previous questions,
until the leaf node is reached,17 indicating finally, whether the per-
son falls under the classification of ‘BC tumour present’ or ‘BC
tumour absent’ group.  
Ensemble algorithms
With ensemble algorithms, results of different base models are
combined, with the aim to improve the overall predictive perfor-
mance in a single model.17 By combining the results from the dif-
ferent models, the strengths and weaknesses of the various models
emerge, correct predictions are reinforced and incorrect predic-
tions get cancelled out.17 Most ensemble algorithms are ‘black
boxes’ because the underlying base models are randomly generat-
ed and are not led by exact prediction rules, and are therefore, not
interpretable.17 In our study, we will use the popular RF ensemble
algorithm. Multiple DTs are created based on different random
subsets of features to form RF.18
Boosting algorithms
Boosting is a category of ensemble algorithms that increases
the performance of multiple weak algorithms by adjusting the
weights of observations from earlier classifications.11,19 If an
observation is misclassified, boosting attempts to increase the
weight of this observation and vice versa. In our study, we will use
three boosting algorithms: i) AdaBoost; iii) GBM; and iii)
XGBoost. These algorithms are based on the DT base algorithm.
The AdaBoost was created by Freund and Schapire;19 GBM was
invented by Friedman;20 and XGBoost was initiated by Chen and
Guestrin.21 We chose these boosting algorithms because they are
known to be powerful and perform well. Furthermore, XGBoost is
known to be a state-of-the-art algorithm and it is also scalable.21
Stratified k-fold cross-validation resampling technique
on training set for each model
The SCV resampling technique will be applied to the training
portion of the BCCD. With SCV, data is split into k equal parts,
where k-1 parts are used to train a model and the remaining last
portion is used to validate the performance of a model,11 with a
guarantee that each part will have representations of both ‘BC
tumour present’ and ‘BC tumour absent’ groups. This is an iterative
process that is repeated k times. We chose the value of k to be ten,
because is generally known to be a very common and good choice
for the folds. This process will therefore be repeated ten times and,
in the end, a model’s performance will be evaluated based on the
average accuracy achieved from the ten folds.  
Parameter tuning the models
With parameter tuning, the internal settings of each algorithm
are adjusted to be optimal values to assist with the learning process
of ML models. This process is like tuning a radio to identify the
correct frequency channel.17 We will use parameter tuning for all
models in this study. Each algorithm has different parameters to
tune. Parameter tuning is important because it results in faster
learning and consequently, improved performances of models.
This process will assist in achieving objective (ii) so that we can
answer research question 01.
Performance metric evaluation methods to assess
model performances
After each model is trained, it will be tested using validation
and test sets. To accomplish this, the following subsections briefly
discuss the metrics that will be used.
A Confusion Matrix (CM) is a table showing actual versus pre-
dicted labels of a ML model for the various classes in a dataset.
Since our dataset contains two classes with the labels ‘BC tumour
present’ and ‘BC tumour absent’, the table forms a two-by-two
dimension. Using CM, we compute the following:
i. True Positive (TP) in row one, column one: The ‘BC tumour
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present’ group is correctly classified as having BC. 
ii. False Negative (FN) in row one, column two: The actual ‘BC
tumour present’ group is incorrectly classified as not having
BC. 
iii. False Positive (FP) in row two, column one: The ‘BC tumour
absent’ group is incorrectly classified as having BC. 
iv. True Negative (TN) in row two, column two: The ‘BC tumour
absent’ group is correctly classified as not having BC.
We will use the following common metrics to evaluate our
models’ performances: i) accuracy; ii) precision; iii) recall or sen-
sitivity; iv) specificity; v) F1 score; vi) Receiver Operating
Characteristic (ROC) curve; and vii) Area Under the ROC Curve
(AUC). The calculations of these metrics are based on CM and are
given by Eqs. 2-6.10,14
The F1 score is known as the harmonic average of recall and
precision.8 The highest value for the F1 score is one and the lowest
value is zero.14 The ROC curve provides a visual depiction of sen-
sitivity on the Y axis against one minus specificity on the X axis,
plotted on a two-dimensional graph.8 The AUC is the entire area
under ROC curve and will highlight the performance of ‘BC
tumour present’ and ‘BC tumour absent’ classes. The lowest value
for AUC is zero and the highest value is one, meaning 100% or
best performance for a model.
The entire modelling process will be programmed on Jupyter
Notebook software using Python version 3.6.5 on an Intel® Core™
i7-8750H Central Processing Unit (CPU) with 16GB RAM
@2.20GHz laptop. Some of the open-source Python packages that
will be used are: Scikit-Learn,22,23 Numpy, Pandas, Matplotlib and
Seaborn. Anaconda distribution will be used for managing package
versioning.
Statistical analysis for model comparison
The Friedman test will be carried out to determine the best
model using all metrics collectively. This will be performed to
achieve objective (iii) so that research question 01 can be
answered. 
The best performing model(s) in this study based on the mean
metrics will be compared to models from the literature. This will
be used to achieve objective (iv) and answer research question 02. 
All statistical tests will be evaluated at 5% level of significance
using the IBM® SPSS Statistics 26 software.  
Additional iterations or changes to the design may be attempt-
ed based on the results of training and testing the models. 
Conclusions
The important features from BCCD found from the modelling
process in this study, together with CFS algorithm, could potential-
ly serve to discover cheap and effective BC biomarkers. This will
be a subset of blood tests. Highest performing model(s) from this
study will serve as basis for future work.
Future work
The BC biomarkers results will be shared with clinicians.
Clinicians may perform clinical trials as complementary analyses
using these results. This will serve a two-fold purpose: i) results
will go through clinical validation step; ii) ii) collection of this data
assists with future modelling using our current study’s hybrid
framework and/or any other ML strategies deemed fit by
researchers. The best performing model(s) from this study could
also be further trained using this new data to enhance its perfor-
mance. Dataset size plays a significant role in model performances
therefore, more data generally equates to better probability of
model accuracy. After rigorous tests from clinical trials and mod-
elling, best performing ML model(s) can be productionized by
serving as basis for creation of an AI tool for clinicians. The tool
may be presented to Food and Drug Administration (FDA). After
FDA-approval, clinicians may use this tool in clinical settings for
BC prediction. Biomarkers may be introduced into clinical settings
globally as a new blood test. The clinician would input patients’
blood data into this tool and the tool would output the likelihood of
BC. This would be a quick and cheap first approach to predict BC
and eventually could lead to the subsequent reduction of the global
BC mortality rate.           
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